Kairos Pharma, Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.9M
- Price
- $1.15
- % Change (Daily % change from the live per-ticker quote feed.)
- -25.81%
- Volume
- 9.9M
About
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Quick stats
Shares outstanding3.4M
Computed float2.3M
Float / shares68.9%
Cash runway (months)7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001962011
Websitehttps://kairospharma.com
AI Summary
AI-generated1/19
minorneutraloperations update
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
Kairos Pharma announced that President and CSO Neil Bhowmick will present and moderate at the 24th Annual Discovery on Target conference in Boston, held Sept. 28 to Oct. 1.
Bhowmick will present an oral plenary on KROS-101, a GITR-targeting candidate for solid tumors, and moderate a breakout session on cancer therapy resistance on Sept. 30.
The release is promotional in nature and contains no new clinical data or financial updates; Kairos' lead candidate remains ENV-105, an anti-CD105 antibody.